Summary:
- This article discusses the effects of a new drug called Inclisiran on reducing low-density lipoprotein (LDL) cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD).
- Inclisiran is a small interfering RNA (siRNA) therapy that targets the PCSK9 gene, which plays a key role in regulating LDL cholesterol levels in the body.
- The study found that Inclisiran was effective in significantly lowering LDL cholesterol levels in patients with ASCVD, potentially offering a new treatment option for those at high risk of heart disease.